Johnson & Johnson Hit With $8 Billion Jury Verdict in Risperdal Suit

A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys. BY MIHIR ZAVERI AND KATIE THOMAS https://ift.tt/31YDhZP https://ift.tt/2p25dxC New York Times Health your-feed-science, Drugs (Pharmaceuticals), Suits and Litigation (Civil), Fines (Penalties) October 9, 2019 at 03:47AM